Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21859
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCampbell, Bruce Cv-
dc.contributor.authorMitchell, Peter J-
dc.contributor.authorChurilov, Leonid-
dc.contributor.authorYassi, Nawaf-
dc.contributor.authorKleinig, Timothy J-
dc.contributor.authorYan, Bernard-
dc.contributor.authorThijs, Vincent N-
dc.contributor.authorDesmond, Patricia M-
dc.contributor.authorParsons, Mark W-
dc.contributor.authorDonnan, Geoffrey A-
dc.contributor.authorDavis, Stephen M-
dc.date2019-09-30-
dc.date.accessioned2019-10-07T21:40:25Z-
dc.date.available2019-10-07T21:40:25Z-
dc.date.issued2020-07-
dc.identifier.citationInternational Journal of Stroke 2020; 15(5): 567-572-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21859-
dc.description.abstractIntravenous thrombolysis with tenecteplase is more effective than alteplase in achieving substantial reperfusion at initial angiographic assessment and improves functional outcome. However, the optimal dose of tenecteplase remains uncertain. We hypothesized that 0.40 mg/kg tenecteplase is superior to 0.25 mg/kg tenecteplase in achieving reperfusion at initial angiogram, when administered within 4.5 h of ischemic stroke onset, in patients planned to undergo endovascular therapy. EXTEND-IA TNK part 2 is an investigator-initiated, phase II, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) study. Eligibility requires a diagnosis of ischemic stroke within 4.5 h of stroke onset, pre-stroke modified Rankin Scale (mRS)≤3 (no upper age limit), absence of contraindications to intravenous thrombolysis, and large vessel occlusion (internal carotid, basilar, or middle cerebral artery) on multimodal CT. Patients are randomized to IV tenecteplase at either 0.40 mg/kg (max 40 mg) or 0.25 mg/kg (max 25 mg) prior to thrombectomy. The primary outcome measure is reperfusion on the initial catheter angiogram, assessed as modified Treatment In Cerebral Infarction (mTICI) 2b/3, or the absence of retrievable intracranial thrombus. Secondary outcomes include mRS at day 90 and early neurological improvement (reduction in National Institutes of Health Stroke Scale (NIHSS) by ≥8 points or reaching 0-1) at day 3. Safety outcomes are death and symptomatic intracerebral hemorrhage. Trial registration: ClinicalTrials.gov NCT03340493.-
dc.language.isoeng-
dc.subjectCT perfusion-
dc.subjectIschemic Stroke-
dc.subjectalteplase-
dc.subjectendovascular thrombectomy-
dc.subjectintra-arterial clot retrieval-
dc.subjectrandomized trial-
dc.subjecttenecteplase-
dc.subjectthrombolysis-
dc.subjecttissue plasminogen activator-
dc.titleDetermining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study.-
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternational Journal of Stroke-
dc.identifier.affiliationDepartment of Medicine, Austin Health, University of Melbourne, Heidelberg, Australiaen
dc.identifier.affiliationDepartment of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Radiology, the Royal Melbourne Hospital, University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationRoyal Adelaide Hospital, Adelaide, South Australia, Australiaen
dc.identifier.doi10.1177/1747493019879652-
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3632-9433-
dc.identifier.orcid0000-0002-9807-6606-
dc.identifier.pubmedid31564231-
dc.type.austinJournal Article-
local.name.researcherChurilov, Leonid
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptNeurology-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.